Cover Image

Guselkumab in Patients with Scalp Psoriasis: A post hoc Analysis of the VOYAGE 2 Phase III Randomized Clinical Trial

Scalp psoriasis affects approximately 80% of patients with psoriasis and can negatively impact their quality of life. This post hoc analysis of the VOYAGE 2 Phase III randomized clinical trial evaluated scalp response to guselkumab treatment and its association with skin response and patient-reporte...

Full description

Saved in:

Bibliographic Details
Main Authors:	Enikö Sonkoly (Author), Julia-Tatjana Maul (Author), Matteo Megna (Author), Patricia Gorecki (Author), Edmée Crombag (Author), Jozefien Buyze (Author), Laura Savage (Author)
Format:	Book
Published:	Medical Journals Sweden, 2024-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial
by: Luis Puig, et al.
Published: (2024)

Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2
by: Byung Soo Kim, et al.
Published: (2023)

Guselkumab - In Psoriasis and Beyond
by: Aditya Kumar Bubna, et al.
Published: (2024)

Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis
by: Ana-Maria Orbai, et al.
Published: (2023)

Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)
by: Kristian Reich, et al.
Published: (2024)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence
by: Ruggiero A, et al.
Published: (2022)

Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy
by: Andrew Blauvelt, et al.
Published: (2024)

Treatment of refractory dissecting cellulitis of the scalp with guselkumab: Case report
by: Sonal Muzumdar, et al.
Published: (2020)

Response Types and Factors Associated with Response Types to Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis from Two Randomized Clinical Trials
by: Alexander Egeberg, et al.
Published: (2024)

Guselkumab for the treatment of psoriasis - evidence to date
by: Miguel Nogueira, et al.
Published: (2019)

Patients with Persistent Mild Psoriasis after Treatment with Ustekinumab Achieved Greater Improvements in Skin Clearance and Patient-reported Outcomes after Switching to Guselkumab in the Phase 3 NAVIGATE Trial
by: Enzo Errichetti, et al.
Published: (2024)

Successful treatment of generalized pustular psoriasis with guselkumab
by: Martina Part
Published: (2024)

No impact of disease duration on response to tildrakizumab treatment among patients with moderate‐to‐severe plaque psoriasis: Post hoc analyses from two phase 3 (reSURFACE 1 and reSURFACE 2) and one phase 4 (TRIBUTE) studies
by: Johannes Griss, et al.
Published: (2023)

Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study
by: Megna M, et al.
Published: (2022)

Rapid Remission of Sunburn-Induced Guttate Psoriasis with Guselkumab
by: Erin Bartholomew, et al.
Published: (2023)

A case of scalp psoriasis resistant to ixekizumab treated with bimekizumab
by: Matteo Megna, MD, et al.
Published: (2023)

Guselkumab-induced vitiligo in a patient with psoriatic arthritis
by: Fabrizio Martora, MD, et al.
Published: (2023)

Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
by: Light JG, et al.
Published: (2021)

Plantar pustules in a psoriasis patient during the guselkumab therapy
by: Shinsuke Nakazawa, et al.
Published: (2021)

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
by: Timothy Fitzgerald, et al.
Published: (2023)

Seven cancer patients receiving Guselkumab for treatment of moderate-to-severe psoriasis
by: Luca Mastorino, et al.
Published: (2022)

Erythrodermic psoriasis treatment with Guselkumab: report of two cases and literature review
by: Esperanza Welsh, et al.
Published: (2024)

Multirefractory bullous pemphigoid, psoriasis and psoriatic arthritis successfully treated with guselkumab
by: Francisco José Rodríguez-Cuadrado, et al.
Published: (2024)

Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis
by: Yang EJ, et al.
Published: (2019)

Outcomes among scalp psoriasis patients: Is scalp psoriasis resistant to topical treatment?
by: Toral S Vaidya, et al.
Published: (2018)

Clinical observation of guselkumab in the treatment of 23 cases of moderate to severe plaque psoriasis
by: Liye XIA, et al.
Published: (2024)

Transcription Factor IRF7 is Involved in Psoriasis Development and Response to Guselkumab Treatment
by: Yuan X, et al.
Published: (2024)

Successful long‐term guselkumab treatment of severe plaque psoriasis in patients with class III obesity: A case series
by: Marco Galluzzo, et al.
Published: (2024)

Efficacy of Secukinumab in Psoriasis: Post Hoc Gender-Wise Analysis of the SUPREME Study
by: Stingeni L, et al.
Published: (2023)

Real-world Data Reveal Long Drug Survival for Guselkumab in Patients with Plaque Psoriasis
by: Marloes E. van Muijen, et al.
Published: (2022)

Effectiveness and tolerability of guselkumab in patients with psoriasis: A longitudinal Belgian retrospective multicenter study
by: Pierre-Dominique Ghislain, MD, et al.
Published: (2021)

The use of ustekinumab and guselkumab in a pediatric psoriasis patient with active hepatitis B infection
by: Eingun James Song, MD, FAAD, et al.
Published: (2021)

Guselkumab for the treatment of severe plaque psoriasis in a schizophrenia patient: a case report
by: Nicoletta Bernardini, et al.
Published: (2022)

Targeting p19 as a treatment option for psoriasis: an evidence-based review of guselkumab
by: Wechter T, et al.
Published: (2018)

Collaboration in the management of psoriasis and psoriatic arthritis: A survey of joint working in UK clinical practice
by: Laura Savage, et al.
Published: (2023)

Long-Term Efficacy of Guselkumab in an Adolescent Hidradenitis Suppurativa Patients: A Case Report
by: Martora F, et al.
Published: (2024)

Drug survival of guselkumab in patients with plaque psoriasis: A 2 year retrospective, multicenter study
by: Yuliya Lytvyn, PhD, et al.
Published: (2021)

Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
by: Timothy Fitzgerald, et al.
Published: (2023)

Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis
by: Tarja Mälkönen, et al.
Published: (2022)

Real-world outcomes in patients with malignancy and moderate-to-severe psoriasis treated with guselkumabCapsule Summary
by: Tamara Gracia Cazaña, MD, PhD, et al.
Published: (2024)